Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Greco

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Biomedical Optics Express|June 14, 2013
Simultaneous spatial and temporal focusing for tissue ablationErica Block, Michael Greco, Dawn Vitek, et al.
ACS Medicinal Chemistry Letters|December 18, 2020
Discovery of PEGylated 6-Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB<sub>1</sub>R Inverse AgonistsYue-Mei Zhang, Michael Greco, Tonya Le Blanc, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|October 26, 2012
Multisource feedback in evaluating the performance of doctors: the example of the UK General Medical Council patient and colleague questionnairesChristine Wright, Suzanne H Richards, Jacqueline J Hill, et al.
BMC Medicine|January 8, 2023
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa studyYuankai Shi, Jianying Zhou, Yanqiu Zhao, et al.
Optics Letters|November 15, 2021
120  mJ, 1  kHz, picosecond laser at 515  nmZbyněk Hubka, Roman Antipenkov, Robert Boge, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2022
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion StudyYuankai Shi, Yanqiu Zhao, Sheng Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2023
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studiesSheng Yang, Shiman Wu, Yanqiu Zhao, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Biomedical Optics Express|June 14, 2013
Simultaneous spatial and temporal focusing for tissue ablationErica Block, Michael Greco, Dawn Vitek, et al.
ACS Medicinal Chemistry Letters|December 18, 2020
Discovery of PEGylated 6-Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB<sub>1</sub>R Inverse AgonistsYue-Mei Zhang, Michael Greco, Tonya Le Blanc, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|October 26, 2012
Multisource feedback in evaluating the performance of doctors: the example of the UK General Medical Council patient and colleague questionnairesChristine Wright, Suzanne H Richards, Jacqueline J Hill, et al.
BMC Medicine|January 8, 2023
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa studyYuankai Shi, Jianying Zhou, Yanqiu Zhao, et al.
Optics Letters|November 15, 2021
120  mJ, 1  kHz, picosecond laser at 515  nmZbyněk Hubka, Roman Antipenkov, Robert Boge, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2022
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion StudyYuankai Shi, Yanqiu Zhao, Sheng Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2023
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studiesSheng Yang, Shiman Wu, Yanqiu Zhao, et al.
Pageof 3